Short Interest in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Decreases By 72.4%

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) saw a significant decrease in short interest in May. As of May 15th, there was short interest totaling 19,453 shares, a decrease of 72.4% from the April 30th total of 70,535 shares. Based on an average trading volume of 159,209 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Wall Street Analyst Weigh In

XTNT has been the subject of several research analyst reports. Craig Hallum restated a “buy” rating on shares of Xtant Medical in a research note on Wednesday, March 18th. BTIG Research restated a “buy” rating and issued a $1.00 price objective on shares of Xtant Medical in a research note on Wednesday, May 13th. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $1.00.

Xtant Medical Stock Performance

Shares of NYSEAMERICAN:XTNT traded down $0.01 on Friday, reaching $0.46. The company’s stock had a trading volume of 109,741 shares, compared to its average volume of 164,503. The stock’s 50-day moving average is $0.51 and its two-hundred day moving average is $0.60. Xtant Medical has a 52-week low of $0.44 and a 52-week high of $0.95. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.34 and a quick ratio of 1.64. The stock has a market capitalization of $64.80 million, a P/E ratio of 46.25 and a beta of -0.11.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its earnings results on Wednesday, May 13th. The medical device company reported ($0.02) EPS for the quarter, meeting analysts’ consensus estimates of ($0.02). Xtant Medical had a net margin of 1.50% and a return on equity of 3.68%. The business had revenue of $20.88 million during the quarter, compared to analysts’ expectations of $20.16 million.

Institutional Investors Weigh In On Xtant Medical

A number of institutional investors and hedge funds have recently made changes to their positions in XTNT. Jane Street Group LLC purchased a new stake in shares of Xtant Medical in the second quarter valued at about $26,000. Nantahala Capital Management LLC raised its holdings in shares of Xtant Medical by 500.3% in the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock valued at $50,543,000 after buying an additional 57,000,000 shares during the last quarter. Mink Brook Asset Management LLC raised its holdings in shares of Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after buying an additional 60,997 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Xtant Medical by 4.6% in the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after buying an additional 104,159 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Xtant Medical in the fourth quarter valued at about $220,000. 69.33% of the stock is owned by hedge funds and other institutional investors.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.